Safety and efficacy of CD19/CD22 CAR T cells in children and young adults with relapsed/refractory ALL

Bookmark and Share
Published: 30 Jun 2020
Views: 123
Rating:
Save
Dr Haneen Shalabi - National Cancer Institute, NIH, Bethesda, USA

Dr Haneen Shalabi speaks to ecancer in an online interview for the virtual AACR 2020 meeting.

She discusses the results of the phase 1 dose-escalation study evaluating the safety and efficacy of CD19/CD22 CAR T cells in children and young adults with relapsed/refractory ALL.

Dr Shalabi goes through the background to the study and talks us through the methodology used.

She reports that the CAR T cells were well tolerated at all dose levels with a reversible side effect profile and patients did respond.